Elevation End Period Cash Flow from 2010 to 2024

ELEV Stock  USD 0.64  0.02  3.23%   
Elevation Oncology End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Elevation Oncology End Period Cash Flow regression line of quarterly data had mean square error of 1119 T and geometric mean of  6,003,452. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
49.3 M
Current Value
71 M
Quarterly Volatility
43.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
  
Check out the analysis of Elevation Oncology Correlation against competitors.
For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Latest Elevation Oncology's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Elevation Oncology over the last few years. It is Elevation Oncology's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Elevation End Period Cash Flow Regression Statistics

Arithmetic Mean27,281,808
Geometric Mean6,003,452
Coefficient Of Variation158.39
Mean Deviation34,055,744
Median1,740,000
Standard Deviation43,210,874
Sample Variance1867.2T
Range144.5M
R-Value0.67
Mean Square Error1119T
R-Squared0.44
Significance0.01
Slope6,434,817
Total Sum of Squares26140.5T

Elevation End Period Cash Flow History

202471 M
202349.3 M
202245.9 M
2021146.3 M
202079.4 M

About Elevation Oncology Financial Statements

Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow49.3 M71 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.